Blood Stream Infection Testing Market Report 2025

This blood stream infection testing market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The blood stream infection testing market size has grown rapidly in recent years. It will grow from $7.59 billion in 2024 to $8.49 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to the rising incidence of hospital-acquired infections, growing prevalence of antimicrobial resistance, increasing aging population, increasing healthcare expenditure, and rising prevalence of chronic diseases.

The blood stream infection testing market size is expected to see rapid growth in the next few years. It will grow to $13.19 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to increasing demand for rapid diagnostic tests, growing adoption of molecular diagnostics, rising focus on personalized medicine, government initiatives for infection control, and rising prevalence of multi-drug-resistant pathogens. Major trends in the forecast period include the growing use of AI in diagnostic tools, integration of telemedicine with diagnostic services, rising demand for home-based testing kits, development of multiplex diagnostic platforms, and growing partnerships between diagnostic companies and hospitals.

The rising prevalence of infectious diseases is projected to drive the growth of the bloodstream infection testing market in the future. Infectious diseases are defined as illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, or parasites. The rates of infectious diseases are increasing due to several factors, such as heightened global travel, urbanization, climate change, antibiotic resistance, and gaps in vaccination coverage. Testing for bloodstream infections is crucial in diagnosing and identifying pathogens responsible for sepsis and other severe infections, enabling targeted and effective treatment. For example, in December 2023, the latest World Malaria Report published by the World Health Organization (WHO), a Switzerland-based United Nations agency, indicated that there were 249 million cases of malaria in 2022, up from 244 million cases in 2021. The estimated number of malaria-related deaths was 608,000 in 2022, compared to 610,000 in 2021. Thus, the increasing prevalence of infectious diseases is driving the bloodstream infection testing market.

Key companies in the bloodstream infection testing market are focusing on product innovation to maintain their market position, particularly by developing blood testing cartridges. These disposable devices are designed to analyze blood samples during diagnostic tests, containing preloaded reagents and integrated sensors or microfluidic channels that help detect specific biomarkers, pathogens, or conditions from a small blood sample. For instance, in August 2022, Immunexpress Pty Ltd., an Australian molecular diagnostics company, introduced SeptiCyte RAPID cartridges. These cartridges utilize undiluted ethylenediaminetetraacetic acid (EDTA) blood as a validated sample type, showing a strong correlation with other blood collection methods in a multi-site European study. This innovation enhances the accuracy and speed of sepsis diagnosis, promoting broader clinical use and potentially transforming patient care while reducing healthcare costs.

In January 2023, Thermo Fisher Scientific Inc., a U.S.-based life science and clinical research company, acquired Binding Site Group Ltd. for $2.8 billion. The acquisition aims to strengthen Thermo Fisher's specialty diagnostics segment by incorporating Binding Site's innovative technologies for diagnosing and monitoring multiple myeloma, enhancing clinical value, accelerating patient outcomes, and contributing to the growth of the diagnostics market. Binding Site Group Ltd., based in the UK, manufactures medical diagnostic products focused on detecting cancer and immune disorders.

Major companies operating in the blood stream infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Siemens Healthcare Private Limited, Becton Dickinson and Company (BD), Grifols S.A., Hologic Inc., BIOMÉRIEUX SA, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., DiaSorin S.p.A., Seegene Inc., Cepheid, Meridian Bioscience Inc., Biocartis NV, T2 Biosystems Inc., Molzym GmbH & Co. KG, Curetis GmbH, Accelerate Diagnostics Inc., OpGen Inc.

North America was the largest region in the blood stream infection testing market in 2024. The regions covered in the blood stream infection testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blood stream infection testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bloodstream infection testing involves diagnostic methods used to detect and identify pathogens such as bacteria, fungi, or viruses in the blood that lead to infections. This process typically includes blood cultures and molecular assays to pinpoint the specific microorganism causing the infection. Accurate and timely detection is essential for the effective treatment and management of conditions such as sepsis and other severe infections.

The primary product categories in bloodstream infection testing include instruments, reagents and consumables, and software and services. Instruments used in bloodstream infection testing refer to the specialized equipment and devices designed to detect and analyze pathogens in blood samples, facilitating precise diagnosis and infection monitoring. Testing is performed on samples such as whole blood or blood cultures, employing technologies such as polymerase chain reaction (PCR), mass spectrometry, in situ hybridization, and others. The end-users of this testing include hospitals and diagnostic centers, laboratory service providers, academic and research institutions, and more.

The blood stream infection testing market research report is one of a series of new reports that provides blood stream infection testing market statistics, including blood stream infection testing industry global market size, regional shares, competitors with a blood stream infection testing market share, detailed blood stream infection testing market segments, market trends and opportunities, and any further data you may need to thrive in the blood stream infection testing industry. This blood stream infection testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blood stream infection testing market consists of revenues earned by entities by providing services such as molecular diagnostics, serological assays, rapid diagnostic tests, next-generation sequencing, and pathogen identification and sensitivity testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood stream infection testing market also includes sales of blood culture media, molecular diagnostics kits, rapid diagnostic tests, automated blood culture systems, microbial identification panels, sepsis biomarker assays, and immunoassay kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.